Article

About Our Sponsor: VIGAMOX™ (moxifloxacin HCl ophthalmic solution)

VIGAMOX™ (moxifloxacin HCl ophthalmic solution) 0.5% as base is theonly FDA-approved fluoroquinolone drop that offers the following featuresand benefits: VIGAMOX™ solution is the only fourth generation fluoroquinolone eye-drop formulated at a 0.5% concentration, providing higher drug concentration throughout the relevant ocular structures.1 Formulated at a pH of 6.8, the near-neutral pH of VIGAMOX™ solution translates directly into excellent comfort, tolerability and increased solubility.1 VIGAMOX™ solution is robust enough to not only meet, but exceed all United States Pharmacopoeia (USP) tests without the need for benzalkonium chloride: this is a direct result of the inherent anti-bacterial andanti-fungal activity of the moxifloxacin formulation itself.2 The active ingredient of VIGAMOX™, solution moxifloxacin, is the only available fluoroquinolone with a bicyclic side-chain at the C-7 position: this reduces the ability of the microbial cell's efflux pump to flush out antibiotic, thus increasing the drug's length of stay in the microorganism, leading to improved efficacy and further inhibition of resistance.1 These unique product attributes speak directly to the benefits that VIGAMOX™ solution brings to ophthalmologists and patients. Please see prescribinginformation at www.vigamox.com.1Alfonso EC, Katz HR, McCulley JP, O'Brien TP. Moxifloxacin 0.5%: a4th generation ocular fluoroquinolone. Excerpts from RefractiveEyecare for Ophthalmologists. March 2003; 7 (suppl):202Moxifloxacin: Antimicrobial efficacy test results. Data on file, AlconLaboratories, Inc.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
I. Paul Singh, MD, speaks about glaucoma treatment and successful ophthalmic / optometric comanagement at the 19th Annual Controversies in Modern Eye Care meeting
© 2025 MJH Life Sciences

All rights reserved.